Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129094 | 0.88 | MAP4K4 (0.56) | MAP4K4CARM1HRH3PRMT6 | |
| SCHEMBL18984688 | 0.88 | MAP4K4 (0.56) | MAP4K4CARM1HRH3PRMT6 | |
| SCHEMBL18129078 | 0.87 | MAP4K4 (0.56) | MAP4K4TGFBR1CARM1MTORHRH3 | |
| SCHEMBL18984649 | 0.83 | MAP4K4 (0.59) | MAP4K4CARM1PRMT6 | |
| SCHEMBL18129157 | 0.80 | MAP4K4 (0.58) | MAP4K4CARM1HRH3PRMT6 | |
| SCHEMBL3435422 | 0.79 | MAP4K4 (0.57) | MAP4K4TGFBR1CARM1MTORPRKD1 | |
| SCHEMBL23124608 | 0.76 | MEN1 (0.61) | TGFBR1HRH3 | |
| SCHEMBL375264 | 0.74 | GRIN2B (0.62) | CARM1HRH3PRMT6 | |
| SCHEMBL15536906 | 0.74 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587413 | 0.73 | ACHE (0.60) | MAP4K4CARM1MTORPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | MAP4K4 4190/4885TGFBR1 533/4885CARM1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.